LOGIN
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis
July 2025
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
J Bone Miner Res . 2023 Oct;38(10):1404-1414.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Five hundred eleven postmenopausal women with osteoporosis were randomized to receive daily transdermal abaloparatide (abaloparatide-sMTS; n=256) or subcutaneous abaloparatide (abaloparatide-SC; n=255) for 12 months. The primary outcome was percentage change in lumbar spine bone mineral density (BMD). Secondary outcomes included changes in total hip and femoral neck BMD, bone turnover markers, der...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.